Europska Unija - hrvatski - EMA (European Medicines Agency)

galderma international - brimonidin tartrat - bolesti kože - ostali dermatološki pripravci - mirvaso je indiciran za simptomatsko liječenje eritema grudi rosacea kod odraslih pacijenata.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

galderma international, tour europlaza, 20 avenue andre prothin, la defense 4, la defense cedex, francuska - adapalen benzoilperoksid - gel - 1 mg/g + 25 mg/g - urbroj: 1 g gela sadrži 1 mg adapalena i 25 mg benzoilperoksida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

galderma international, tour europlaza, 20 avenue andre prothin, la defense 4, la defense cedex, francuska - trifaroten - krema - urbroj: jedan gram kreme sadrži 50 mikrograma trifarotena

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

galderma international, tour europlaza, 20 avenue andre prothin, la defense 4, la defense cedex, francuska - adapalen benzoilperoksid - gel - urbroj: jedan gram gela sadrži 3 mg adapalena i 25 mg benzoilperoksida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bosnalijek d.o.o., zagreb - prevencija i pomoć pri liječenju neinficiranih, površinskih ozljeda na koži

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinib maleata - agenti za dermatitis, isključujući kortikosteroide - psi - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Europska Unija - hrvatski - EMA (European Medicines Agency)

leo pharma a/s - takrolimus - dermatitis, atopic - ostali dermatološki pripravci - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. javlja četiri ili više puta godišnje), koji su imali početni odgovor za najviše šest tjedana terapije, dva puta dnevno masti tacrolimus (mjesta očistili, gotovo izbrisani ili slabo utječe).

Europska Unija - hrvatski - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - Азацитидин betapharm indiciran za liječenje odraslih bolesnika koji nemaju pravo na hematopoetski transplantacija matičnih stanica (ТГСК) s:middleware-2 i visokog rizika миелодиспластические sindroma (mds) prema međunarodnoj prognozu sustav bodovanja (ipss),kronični миеломоноцитарный leukemije (ХММЛ) od 10% do 29 % бластов koštane srži, bez миелопролиферативные poremećaja,akutnog миелоидного leukemije (aml) od 20% do 30 % бластов i multi-porijeklo displazije, prema podacima svjetske zdravstvene organizacije (who) za klasifikaciju aml s > 30 % бласты koštane srži prema klasifikaciji svjetske zdravstvene organizacije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresivi - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psorijatični arthritiscosentyx, odvojeno ili u kombinaciji sa metotreksatom (mtx), propisan za liječenje aktivnog psorijatični artritis kod odraslih pacijenata, kada je odgovor na prethodna bolest дорабатывая anti-reumatskih lijekovi (dmards) terapija je bila neadekvatna.. Аксиальный спондилоартрит (axspa)ankilozantni спондилоартрит (kao, радиографические osi спондилоартрит)cosentyx indiciran za liječenje aktivnog анкилозирующего спондилита kod odraslih, koji su adekvatno odgovorili na standardnu terapiju. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.